Serological tests for COVID-19: Potential opportunities

Marcarious M Tantuoyir; Nima Rezaei

doi:10.1002/cbin.11516

Serological tests for COVID-19: Potential opportunities

Cell Biol Int. 2021 Apr;45(4):740-748. doi: 10.1002/cbin.11516. Epub 2021 Jan 13.

Authors

Marcarious M Tantuoyir^{1

2

3}, Nima Rezaei^{1

4

5}

Affiliations

¹ School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
² Biomedical Engineering Unit, University of Ghana Medical Center (UGMC), Accra, Ghana.
³ Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Accra, Ghana.
⁴ Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
⁵ Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel betacoronavirus, caused a pandemic leading to a standstill of nearly all global activities. There are some controversies on the production of specific immunoglobulin M (IgM) and IgG antibodies after the infection with SARS-CoV-2. This paper seeks to elaborate on the potential application of IgM and IgG antibodies and the viral antigens for the diagnosis and the course of the disease as well as the recurrence of positive nucleic acid tests after discharge.

Keywords: IgG; IgM; SARS-CoV-2; antibody; coronavirus; diagnosis.

Publication types

Review

MeSH terms

Antibodies, Viral / blood*
Antigens, Viral / immunology
COVID-19 / immunology
COVID-19 / pathology*
COVID-19 / virology
COVID-19 Vaccines / immunology
Humans
Immunoglobulin G / blood
Immunoglobulin M / blood
SARS-CoV-2 / immunology*
SARS-CoV-2 / isolation & purification
SARS-CoV-2 / metabolism
Serologic Tests

Substances

Antibodies, Viral
Antigens, Viral
COVID-19 Vaccines
Immunoglobulin G
Immunoglobulin M